GlassScriptPhysician profile
Madeline Baxter
NPI 1669046314
$4,415.59
in general payments reported to CMS, 2019-2025
38 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $648 · 2023: $1,129 · 2024: $1,176 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,263.70 | 2021-2025 | |
| Gilead Sciences, INC. | $862.05 | 2021-2025 | Descovy, Yeztugo |
| Novo Nordisk INC | $677.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $231.12 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.16 | 2022-2025 | Hyqvia, Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $103.50 | 2022 | |
| Shield Therapeutics INC | $88.84 | 2025 | |
| Eisai INC. | $84.90 | 2021-2024 | |
| Viiv Healthcare Company | $81.25 | 2024-2025 | Apretude |
| Incyte Corporation | $72.30 | 2021-2024 | Opzelura |
| Exeltis, USA INC. | $69.18 | 2024-2025 | Slynd |
| Lilly USA, LLC | $65.84 | 2022-2024 | Trulicity, Mounjaro, Zepbound |
| Alexion Pharmaceuticals, INC. | $57.84 | 2024 | Ultomiris |
| Neos Therapeutics, LP | $52.30 | 2022 | |
| Vertos Medical, INC. | $48.36 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.61 | 2023 | Cologuard Collection Kit |
| Tg Therapeutics, INC. | $45.00 | 2024 | |
| Tris Pharma INC | $37.49 | 2022-2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $37.13 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $36.88 | 2023-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $34.22 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $31.26 | 2023 | Otezla |
| Ardelyx, INC. | $26.19 | 2025 | Ibsrela |
| Corium, LLC | $22.27 | 2023 | Azstarys |
| Alkermes, INC. | $21.60 | 2024 | Vivitrol |
| Kaleo, INC. | $20.20 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $19.51 | 2023 | Prehevbrio |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2022 | |
| Millicent US INC | $18.84 | 2025 | Femlyv, Intrarosa |
| Astrazeneca Pharmaceuticals LP | $17.26 | 2024 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $15.62 | 2023 | Qelbree |
| Acarix USA INC. | $15.27 | 2023 | Cadscor System |
| Evoke Pharma, INC. | $14.96 | 2022 | |
| Noven Therapeutics, LLC | $14.48 | 2024 | Xelstrym |
| Depuy Synthes Sales INC. | $14.42 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.74 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.